**Supplementary Table 3. Distribution of colorectal cancer cases according to SMAD4 expression status and immune response to the tumor in validation cohort**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  | SMAD4 expression status |  |
| Immune response | All cases |  | Lost | Intact | *P*\* |
|  |  |  |  |  |  |
| Tumor-infiltrating lymphocytes (n = 223) |  |  |  |  | 0.005 |
|  Negative/low | 145 (65%) |  | 40 (82%) | 105 (60%) |  |
|  Intermediate | 37 (17%) |  | 5 (10%) | 32 (18%) |  |
|  High | 41 (18%) |  | 4 (8.2%) | 37 (21%) |  |
|  |  |  |  |  |  |
| Intratumoral periglandular reaction (n = 224) |  |  |  |  | 0.088 |
|  Negative/low | 8 (3.6%) |  | 2 (4.1%) | 6 (3.4%) |  |
|  Intermediate | 184 (82%) |  | 44 (90%) | 140 (80%) |  |
|  High | 32 (14%) |  | 3 (6.1%) | 29 (17%) |  |
|  |  |  |  |  |  |
| Peritumoral lymphocytic reaction (n = 224) |  |  |  |  | 0.081 |
|  Negative/low | 12 (5.4%) |  | 4 (8.2%) | 8 (4.6%) |  |
|  Intermediate | 184 (82%) |  | 42 (86%) | 142 (81%) |  |
|  High | 28 (13%) |  | 3 (6.1%) | 25 (14%) |  |
|  |  |  |  |  |  |
| Crohn’s-like lymphoid reaction (n = 165) |  |  |  |  | 0.33 |
|  Negative/low | 117 (71%) |  | 28 (76%) | 89 (70%) |  |
|  Intermediate | 36 (22%) |  | 9 (24%) | 27 (21%) |  |
|  High | 12 (7.3%) |  | 0 | 12 (9.4%) |  |
|  |  |  |  |  |  |

\* *P* value was calculated using the Spearman correlation test between SMAD4 expression status and each lymphocytic reaction variable [ordinal; negative/low (0), intermediate (1), and high (2)].